Health Care & Life Sciences » Pharmaceuticals | Bellerophon Therapeutics Inc.

Bellerophon Therapeutics Inc.

Bellerophon Therapeutics Inc.
Stock Exchange NASDAQ Stock Market
EPS
$0.06
Market Cap
$43.14 M
Shares Outstanding
68.91 M
Public Float
50.21 M

Profile

Address
184 Liberty Corner Road
Warren New Jersey 07059
United States
Employees -
Website http://www.bellerophon.com
Updated 07/08/2019
Bellerophon Therapeutics, Inc clinical-stage therapeutics company, which focuses on developing innovative products at the intersection of drugs and devices that address significant unmet medical needs in the treatment of cardiopulmonary diseases. The company engages in two programs including INOpulse and BCM. INOpulse is based on proprietary pulsatile nitric oxide delivery device.

Financials

View All

Jonathan M. Peacock
Chairman
Fabian Tenenbaum
Chief Executive Officer & Director